CSRC approves Zhensheng Technology to list on the Shanghai Stock Exchange Science and Technology Innovation Board for IPO registration.
On April 17th, the China Securities Regulatory Commission issued the "Approval of the Chongqing Zhenbao Technology Co., Ltd.'s initial public offering of shares registration."
On April 17th, the China Securities Regulatory Commission issued the approval for the initial public offering of Chongqing Zhenbao Technology Co., Ltd. It is reported that Zhenbao Technology plans to list on the Shanghai Stock Exchange Science and Technology Innovation Board, with CITIC SEC as the sponsor, aiming to raise 1.198 billion yuan.
According to the prospectus, Zhenbao Technology specializes in providing manufacturing equipment vacuum chamber internal components and surface treatment solutions for customers in the integrated circuit and display panel industries. The company's main products are equipment components such as silicon, quartz, silicon carbide, and alumina ceramics, as well as surface treatment services such as thermal spraying regeneration, anodizing, and precision cleaning.
The company's semiconductor equipment components have been mass applied in the fields of advanced process integrated circuit manufacturing for logic class 14nm and below technology nodes, advanced process 3DNAND flash memory chip manufacturing with 200 layers and above stacking for storage class, and advanced process storage chip manufacturing for DRAM with 20nm and below technology nodes. According to data from Frost & Sullivan, by 2024, among domestic semiconductor equipment component companies supplying wafer factories directly, the company ranks first in the silicon component market with a revenue market share of 4.5%, and ranks first in the quartz component market with a revenue market share of 8.8%.
Related Articles

New stock news | Fylaland submits application to Hong Kong Stock Exchange for China's largest smart pool equipment supplier.

New stock news | Capital (601136.SH) submits a second application to the Hong Kong Stock Exchange, with total revenue exceeding 3.6 billion yuan in 2025.

Jiangsu Kanion Pharmaceutical (600557.SH) has received the approval notice for the clinical trial of Qingcan Tongluo Granules.
New stock news | Fylaland submits application to Hong Kong Stock Exchange for China's largest smart pool equipment supplier.

New stock news | Capital (601136.SH) submits a second application to the Hong Kong Stock Exchange, with total revenue exceeding 3.6 billion yuan in 2025.

Jiangsu Kanion Pharmaceutical (600557.SH) has received the approval notice for the clinical trial of Qingcan Tongluo Granules.

RECOMMEND

Hong Kong Hard‑Tech Companies Enhance Canton Fair Presence As Veterans And Newcomers Expand International Networks
17/04/2026

Thousand‑Fold Oversubscription In Hong Kong IPOs Signals Multiple Market Shifts
17/04/2026

Rising Compute Costs Drive Industry Price Increases As Institutions Expect Internet Firms To Outperform In Q1
17/04/2026


